PedAM
Pediatric Disease Annotations & Medicines
| Disease | ovarian cancer |
| Symptom | C0220656|malignant ascites |
| Sentences | 35 |
| PubMedID- 23644922 | The existing literature concerning the use of catumaxomab for the treatment of malignant ascites associated with ovarian cancer until today is reported in this article. |
| PubMedID- 24659268 | The management of refractory malignant ascites (ma) due to ovarian cancer (oc) remains a difficult clinical problem. |
| PubMedID- 20332449 | Angiogenesis in the peritoneal cavity arising from ovarian cancer leads to peritoneal carcinomatosis, malignant ascites formation, morbidity and high mortality. |
| PubMedID- 23784932 | We also show that cd163 expression and clinical outcome are linked to il-6 and il-10 present in the malignant ascites of ovarian cancer patients. |
| PubMedID- 23593315 | Il-6 is expressed by primary human ovarian surface epithelial cells and has been detected profoundly higher in tumor tissue . |
| PubMedID- 22901285 | This is the first report on caf markers in malignant ascites and on sumoylation of oct-4a in ovarian cancer. |
| PubMedID- 22927770 | To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced ovarian cancer. |
| PubMedID- 25594018 | These results demonstrate that malignant ascites induce apoptosis of ovarian cancer cells and encourage us to think about the clinical management of ovarian cancer patients with malignant ascites. |
| PubMedID- 24093089 | More than one third of ovarian cancer patients present with malignant ascites at diagnosis; additionally, development of ascites is a fundamental part of chemoresistant and recurrent disease (2, 3). |
| PubMedID- 23159815 | Conclusions: the 13-item facit-ai has content validity among women with malignant ascites associated with ovarian cancer. |
| PubMedID- 25254563 | Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase ii study. |
| PubMedID- 23762304 | We used anti-cd326 microbeads (bd biosciences) and an automacs system (miltenyi biotec, bergisch gladbach, germany) to enrich epithelial cells from malignant ascites of ovarian cancer cases before the aldefluor assay. |
| PubMedID- 22915981 | The aim's measurement properties were assessed using data from two international trials, including 59 ovarian cancer patients with symptomatic malignant ascites. |
| PubMedID- 24849730 | Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites. |
| PubMedID- 24124397 | In addition, clinical trials exploring the use of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer are reviewed. |
| PubMedID- 22235224 | Catumaxomab was also tested in a phase i/ii dose-escalating study on 23 women affected by advanced ovarian cancer with symptomatic malignant ascites containing epcam+ tumour cells . |
| PubMedID- 22934267 | This was associated with increased duration of contacts between t cells and tumor cells and followed by the release of granzyme b, perforin, ifnγ, tnfα, il-10 and tgfβ in xenograft tumors.3 importantly, intraperitoneal application of our bsab reduced malignant ascites in patients with advanced ovarian cancer,4 suggesting that even late stages of cancer are susceptible. |
| PubMedID- 21278244 | Purpose: ovarian cancer patients with malignant ascites have poor prognosis. |
| PubMedID- 19952960 | Thus, our data suggest a relevant role for repeated activation of cells and cytokines of innate immunity in the therapy of ovarian cancer patients with malignant ascites. |
| PubMedID- 26462841 | Meanwhile, we also found that vegf levels in malignant ascites from patients with ovarian cancer were higher than those with other cancers. |
| PubMedID- 22101807 | Iiplatinum-resistant and topotecan and/or liposomal doxorubicin-resistant advanced ovarian cancer with recurrent symptomatic malignant ascitesfirst results demonstrated the efficacy of two weekly intravenous aflibercept in prolonging the time to repeat paracentesis in 8 out of 10 evaluable patients.coleman et al. |
| PubMedID- 25193855 | Sphere forming cells (multicellular spheroids) present in malignant ascites of patients with ovarian cancer represent a major impediment to effective treatment. |
| PubMedID- 26077418 | Methods: exosomes were purified from various body fluids such as amniotic fluid, liver cirrhosis ascites and malignant ascites of ovarian cancer patients and from the condition medium of ovm, and skov3 cell lines by differential centrifugation and sucrose gradient fractionation. |
| PubMedID- 24692682 | malignant ascites in ovarian cancer and the role of targeted therapeutics. |
| PubMedID- 22904615 | Aflibercept has also been used to treat symptomatic malignant ascites in patients with recurrent ovarian cancer.17 the mean time to repeat paracentesis was longer when patients were treated with aflibercept (55 days) as compared with placebo (22 days). |
| PubMedID- 21909397 | However, the malignant ascites associated with ovarian cancer is a physiological niche from which tumour associated nk cells and autologous tumour cells can be relatively easily prepared and such tumour-associated nk cells are subject to localised inhibition . |
| PubMedID- 25833224 | Exs preparations isolated from malignant ascites of ovarian cancer patient #1 are contaminated by lipoprotein particles (smaller than exs, black asterisks) and sporadic mvs (larger than exs, black arrows), the latter are detected by fc also in (b). |
| PubMedID- 20072701 | A phase ii trial of vegf-trap in advanced ovarian cancer patients with recurrent symptomatic malignant ascites has been completed but not yet reported. |
| PubMedID- 25806106 | Recently, a phase ii study of catumaxomab in chemotherapy-refractory ovarian cancer patient with malignant ascites demonstrated a benefit for catumaxomab therapy: catumaxomab prolonged both the puncture free interval and the time to first therapeutic puncture as well as producing improvement in quality of life . |
| PubMedID- 25061503 | Tumor spheroids, non-adherent multicellular aggregates, are present in the malignant ascites of ovarian cancer patients. |
| PubMedID- 24466130 | Reported that cells isolated from malignant ascites of ovarian cancer patients show novel phenotype and induce chemoresistance in tumor cells . |
| PubMedID- 22192729 | Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. |
| PubMedID- 21694727 | For example, catumaxomab is a trifunctional monoclonal antibody (anti-epcam × anti-cd3) approved to treat ovarian cancer patients with malignant ascites (bokemeyer, 2010). |
| PubMedID- 23761327 | Using cells isolated from the malignant ascites of patients with advanced ovarian cancer, we show that "helper" nk cell-inducing factors can be used to enhance local production of teff cell-recruiting chemokines. |
| PubMedID- 20398289 | More recently, using an experimental model of ovarian cancer with malignant ascites formation, we demonstrated that, chronic treatment with abz leads to suppression of vegf levels, inhibition of malignant ascites formation and arrest of tumor growth . |
Page: 1